YCBDcbdMD, Inc.
This year, cbdMD, Inc. (YCBD) has to prove it’s more than a regulatory holding company — the next catalyst is Regulatory & Labeling Development on 2026-09-30, which anchors the price at $0.45, with both bull and bear paths unresolved but leaning slightly bull. If it clears that hurdle, the company could pivot toward the Q3 2026 earnings release, where the market is already pricing in a bearish outcome with a $0.40 fallback, though the bull case still holds at $0.65. The real test comes in 2027, when the Q2 earnings release is expected to retest the $0.40 anchor, with a narrow range between $0.38 and $0.42 — a tight band that suggests the market is already skeptical of the company’s ability to sustain growth.
The schedule
- Wed30Sep
- Thu15Oct
- Thu12Nov
Quarterly earnings report with guidance for Q3 2026
- Thu11Feb
- Thu13May
- Thu12Aug
Past
- Thu13Aug
Actual outcome: Bear · $0.48 at outcome
cbdMD reported 20% year-over-year revenue growth for the quarter, driven by Oasis Beverage momentum and a full quarter of Bluebird Botanical contributions, while meeting EPS estimates with a loss of $0.084 per share. Despite the strong top-line performance, the stock fell 12.3% to hit the bear floor of $0.50. The negative price action indicates that ongoing concerns over the company's unprofitability and cash burn overshadowed the revenue growth.
Q2 2026 earnings will show whether cbdMD can sustain high-teens revenue growth while narrowing losses and stabilizing cash burn, a key test for balance-sheet confidence at $0.69.